Outlook Therapeutics, Inc. (OTLK): Price and Financial Metrics
GET POWR RATINGS... FREE!
OTLK Stock Price Chart Interactive Chart >
OTLK Price/Volume Stats
Current price | $1.27 | 52-week high | $2.12 |
Prev. close | $1.27 | 52-week low | $0.68 |
Day low | $1.25 | Volume | 465,400 |
Day high | $1.30 | Avg. volume | 587,000 |
50-day MA | $1.08 | Dividend yield | N/A |
200-day MA | $1.17 | Market Cap | 325.97M |
Outlook Therapeutics, Inc. (OTLK) Company Bio
Outlook Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The Company engages in identifying, developing, manufacturing, and commercializing complex biosimilar therapeutics. Outlook Therapeutics focuses on monoclonal antibodies in the disease areas of immunology and oncology aspects. Outlook Therapeutics offers its services in the United States.
Latest OTLK News From Around the Web
Below are the latest news stories about OUTLOOK THERAPEUTICS INC that investors may wish to consider to help them evaluate OTLK as an investment opportunity.
Outlook Therapeutics® to Present at the SVB Securities Global Biopharma Conference– Russ Trenary, President and Chief Executive Officer of Outlook Therapeutics to present on Tuesday, February 14th at 4:20 PM ET –ISELIN, N.J., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that Russ Trenary, President and Chief Executive Officer of Outlook Therapeutics, will present at the SVB Securi |
Outlook draws bullish views at Cantor on potential FDA nod for lead asset
|
Outlook Therapeutics® Strengthens Medical Affairs and Commercial Expertise with Appointments of Surendra Sharma, MD, Senior Vice President of Medical Affairs and Glen Olsheim, Executive Director of Commercial ExcellenceDr. Sharma and Mr. Olsheim bring more than 30 years of combined experience in the global pharmaceutical and biotechnology industry from their various roles launching and commercializing ophthalmic productsISELIN, N.J., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced the appointments of Surendra Sharma, |
JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19thJTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced it will host the Virtual Investor 2023 Companies to Watch Event, January 17-19, 2023. |
Outlook Therapeutics® to Present at the Virtual Investor 2023 Companies to Watch EventLive video webcast presentation on Tuesday, January 17th at 11:00 AM ETISELIN, N.J., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that Russ Trenary, President and Chief Executive Officer of Outlook Therapeutics will present at the Virtual Investor 2023 Companies to Watch Event on Tuesday, January 17, |
OTLK Price Returns
1-mo | 18.69% |
3-mo | 15.45% |
6-mo | 5.83% |
1-year | -7.97% |
3-year | 25.74% |
5-year | N/A |
YTD | 17.59% |
2022 | -20.59% |
2021 | 4.62% |
2020 | 120.34% |
2019 | -85.25% |
2018 | N/A |
Continue Researching OTLK
Here are a few links from around the web to help you further your research on Outlook Therapeutics Inc's stock as an investment opportunity:Outlook Therapeutics Inc (OTLK) Stock Price | Nasdaq
Outlook Therapeutics Inc (OTLK) Stock Quote, History and News - Yahoo Finance
Outlook Therapeutics Inc (OTLK) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...